Navigation Links
Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
Date:10/24/2007

SAN MATEO, Calif., Oct. 24 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company, reported results of a Phase II clinical trial of its first compound, A-002, for the treatment of cardiovascular disease. The trial results suggest that treatment with A-002 resulted in significant reductions in blood levels of total cholesterol, Non- High Density Lipoprotein Cholesterol (non HDL-C), and Low Density Lipoprotein Cholesterol (LDL-C), known as "bad" cholesterol, coupled with equally meaningful reductions of C-Reactive Protein (CRP), a recognized marker of inflammation and cardiovascular risk. Decreases in these levels with A-002 treatment were most significant among patients already on a background of statin therapy.

The Phase II PLASMA trial (Phospholipase Levels And Serological Markers of Atherosclerosis) was a multi-center, randomized, double-blind, placebo- controlled trial that enrolled approximately 400 patients with stable coronary heart disease in the U.S. and Ukraine. Subjects were randomized to receive one of four different doses of A-002 or placebo for up to eight weeks. Patients also received doctor-determined standard of care therapies. The primary endpoint, a reduction in secretory phospholipase A2 (sPLA2) levels was achieved with a high degree of statistical significance. In addition, the results also demonstrated clinically meaningful as well as statistically significant decreases in cholesterol levels (LDL-C, non-HDL and total cholesterol) in patients with stable coronary heart disease. Clinically meaningful decreases in inflammation, as measured by levels of CRP, were also observed in the relevant patient population. Full data will be presented in a scientific journal during 2008.

"The results of the PLASMA trial support our belief that A-002's unique mechanism of action has a dual effect on lipids and inflammation, which could provide significant therapeutic benefit to patients currently on backgroun
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015 NorthStar Anesthesia , one ... it has been selected by Mercy, based in ... four of their hospitals:  Mercy St. Vincent  Medical Center and ... , Mercy St. Charles  Hospital in Oregon ... Tiffin . "As we looked to ...
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ ... announced the issuance of a white paper on the ... spray product.  The white paper was presented to the ... by Dr. James H. Anderson, Jr. , MD, ... be viewed online on the Generex website. ...
(Date:8/27/2015)...  BioElectronics Corporation (OTC Pink: BIEL), the maker of ... featuring the use of ActiPatch®, its novel musculoskeletal pain ... Congress of the European Pain Federation EFIC®, ... The Company will also be exhibiting at the Congress ... , department clinical and experimental rheumatology from the University ...
Breaking Medicine Technology:Four Mercy Hospitals in Northwest Ohio Select NorthStar Anesthesia 2Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2
... BURLINGTON, Mass., Dec. 7, 2010 ... cardiovascular diagnostic imaging technologies, today announced the publication of ... association of stent thrombosis with lipid core plaque as ... is the first and only FDA-approved system to provide ...
... 2010 Cymetrix, a leader in providing healthcare ... announced an alliance with Siemens Healthcare for financial ... partnership, Cymetrix will assist in the transition of ... systems to Siemens Soarian®. Cymetrix,s system conversion solution ...
Cached Medicine Technology:InfraReDx Announces Publication of a Case Report in Circulation Highlighting Novel Clinical Finding with LipiScan™ Coronary Imaging System 2Cymetrix Forms Alliance With Siemens Healthcare for System Conversion Support 2
(Date:8/28/2015)... Beach, FL. (PRWEB) , ... August 28, 2015 ... ... problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach ... believes that it should begin with the employer and employees getting together for ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... patient loyalty at a low cost. Personalized with practice contact information and logos, ... patients. Dental offices can also incorporate Calendars into seasonal mailings, thank you and ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics ... to go deep sea diving. The act of recreational diving exposes the ... these reasons, it is vital that all recreational and professional divers undergo regular ...
(Date:8/28/2015)... ... 28, 2015 , ... Popular review site Top5MillionaireDatingSites.com recently published ... . According to the listings, MillionaireMatch.com bags the top spot while ... spokesperson of Top5MillionaireDatingSites.com said, “This website has been designed to assist ...
(Date:8/28/2015)... ... August 28, 2015 , ... Inc. magazine today ranked PREVENT Life Safety ... the nation’s fastest-growing private companies. The list was unveiled online at Inc.com and is ... the last three years, PREVENT ranks higher on the list than any other company ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... the gold standard for detecting colon cancer. But many patients ... invasive test.// Recently, a fecal occult blood stool test has ... stool. However, the test misses a majority of cancers. The ... say the results are encouraging. ,“A simple, non-invasive test ...
... unknown origin are the eighth leading type of cancers. ... Profiling // may now help identify where tumors first ... about 86-percent accurate in determining a tumor’s origin. ... tumor type. Giving the wrong treatment may slow recovery ...
... change in body position may increase an individual’s chances of ... recent study . ,The research is based on a ... or a transient ischemic attack (TIA), also known as a ... common, occur when blood flow to the brain is reduced. ...
... treatment with the oral drug bosentan (Tracleer) has led ... arterial hypertension ( PAH) // . ,PAH is ... is believed to cause the overproduction of endothelin, which ... obstructed. This chronic obstruction leads to PAH, a condition ...
... shows a diet rich in omega-3 and omega-6 fatty acids may ... Researchers say they studied mice to determine the effects of a ... animals were divided into four groups. The first received a diet ... a diet rich in omega-6 fatty acids along with the drug ...
... According to latest research patients who were treated for ... of vitamin B12 in their blood.// An increasing amount ... B and depression, but the specifics have not been ... relationship of vitamin B12 and the treatment of depression. ...
Cached Medicine News:
Inquire...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Multi-Tier Shaker...
... shake up to 16 of AutoGen's tube units ... This new system is most appropriate for bacterial ... digestion. Now you can further simplify your ... our AutoIncubator 96 and then placing our 6-hole ...
Medicine Products: